肿瘤防治研究2026，Vol.53Issue(6)：430-439,10.DOI:10.3971/j.issn.1000-8578.2026.25.0871
VIPR2作为食管腺癌免疫浸润及预后生物标志物的生物信息学分析
Bioinformatics Analysis of VIPR2 as A Biomarker for Immune Infiltration and Prognosis in Esophageal Adenocarcinoma
摘要
Abstract
Objective To investigate the expression characteristics,prognos-tic value,and correlation with immune infiltration of vasoactive intestinal peptide receptor 2(VIPR2)in esophageal adenocarcinoma(ESAD).Methods Transcri-ptome data of 80 ESAD and 10 normal tissues were retrieved from the TCGA database.Immune-related differential genes were identified by integrating the ImmPort database.Cox regression analysis was applied to evaluate the prognostic significance of VIPR2.GSVA and ssGSEA were employed to assess the association between VIPR2 and immune-cell infiltr-ation.Functional enrichment was performed using GO,KEGG,and GSEA.Results VIPR2 expression was significantly down-regulated in ESAD tissues(P<0.05).High VIPR2 expression was associated with prolonged overall survival(HR=0.246,P=0.047),serving as an independent prognostic factor.Fifteen immune-cell types,including CD8+T cells,NK cells,and dendritic cells,showed significantly higher infiltration in the VIPR2-high group,whereas Th17-cell abundance was decre-ased(P<0.05).Enrichment analyses revealed that VIPR2 par-ticipated in multiple tumor-immune pathways and was posi-tively correlated with PD-1 and CTLA-4 expression(P<0.01).Conclusion VIPR2 may serve as a potential biomarker in the prognostic assessment and could modulate the tumor-immune microenvironment in ESAD.关键词
食管腺癌/VIPR2/免疫浸润/生物标志物/预后/生物信息学Key words
Esophageal adenocarcinoma/VIPR2/Immune infiltration/Biomarker/Prognosis/Bioinformatics分类
医药卫生引用本文复制引用
赵珂,刘磊,王桂阁,张家齐,杨丽冰,郭超,黄诚,陈野野,李单青..VIPR2作为食管腺癌免疫浸润及预后生物标志物的生物信息学分析[J].肿瘤防治研究,2026,53(6):430-439,10.基金项目
中国医学科学院医学与健康科技创新工程项目(2023-I2M-C&T-B-019) （2023-I2M-C&T-B-019）
中央高水平医院临床科研业务费(2025-PUMCH-A-177) Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(No.2023-I2M-C&T-B-019) （2025-PUMCH-A-177）
National High Level Hospital Clinical Research Funding(No.2025-PUMCH-A-177) （No.2025-PUMCH-A-177）
